This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Edwards Lifesciences Identifier:
First received: July 26, 2010
Last updated: September 20, 2016
Last verified: September 2016
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards PERIMOUNT Magna Ease Valves in patients undergoing aortic valve replacement with or without concomitant procedures requiring cardiopulmonary bypass.

Condition Intervention Phase
Coronary Artery Disease Aortic Valve Disorder Heart Failure Aortic Valve Stenosis Aortic Valve Insufficiency Device: Implantation of CEP Magna Ease Model 3300TFX Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis in the Aortic Position, Model 3300TFX

Resource links provided by NLM:

Further study details as provided by Edwards Lifesciences:

Primary Outcome Measures:
  • Long term safety performance will be evaluated by comparing the linearized yearly rates listed below to the objective performance criteria (OPC) referenced in the Food and Drug Administration (FDA) 1994 Draft Heart Valve Guidance [ Time Frame: Entire study period (8 yrs post implant) ]
    a) Thromboembolism, b) All Hemorrhage, c) All Perivalvular Leak, d) Endocarditis

Secondary Outcome Measures:
  • Early rates, late linearized rates, and actuarial rates [ Time Frame: Entire study period (8 yrs post implant) ]
    Early rates, late linearized rates, and actuarial rates of: a) Thromboembolism b) Valve Thrombosis, c) All Hemorrhage, d) Major Hemorrhage, e) All Perivalvular leak, f) Major perivalvular leak, g) Endocarditis, h) Hemolysis, i) Structural valve deterioration, j) Non-structural valve dysfunction, k) Reoperation, l) Explant, m) Death, n) Valve Related death

Estimated Enrollment: 225
Study Start Date: October 2007
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
CEP Aortic Bioprothesis, model 3300TFX Device: Implantation of CEP Magna Ease Model 3300TFX
Heart Valve Surgery
Other Name: CEP Magna Ease MOdel 3300TFX

Detailed Description:
This is a prospective, single-arm, multi-center, interventional study to be conducted in the US and outside the US (OUS). This study will enroll a minimum of 225 patients implanted with the study valve in order to achieve 101 aortic valve replacement subjects each followed for a minimum of 8 years. The study will include male and female patients, 18 years or older, requiring replacement for a diseased, damaged or malfunctioning natural or prosthetic aortic valve. Patients will be followed and assessed after implant annually for a minimum of 8 years.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary
  • Require replacement aortic valve
  • Signed informed consent

Exclusion Criteria:

  • Primary
  • Active endocarditis (< 3 mths)
  • Abnormal Ca metabolism
  • Aneurismal aortic degenerative condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01171625

United States, California
Mercy General Hospital
Sacramento, California, United States, 95819
United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States, 08103
Morristown Memorial Hospital
Morristown, New Jersey, United States, 09762
United States, Oregon
Providence Heart & Vascular Institute
Portland, Oregon, United States, 97225
United States, Utah
St. Marks Hospital
Salt Lake City, Utah, United States, 84124
Universitatslinik fur Chirurgie
Anichstr. 35, Innsbruck, Austria, 6020
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
St. Paul's Hospital
Vancouver, Canada, V6Z 1Y6
Liknik fur Herz und BefaBchirurgie Im Deuschen Herzzentrum
Munich, Lazarettstr, Germany, 36
Klinik fur Herz-, Thorax-, Transplantations- und Gefabchirurgie
Hannover, Germany, D-30625
Hospital Peutra de Hierro
San Martin de Porres 4, Madrid, Spain, CP-28035
United Kingdom
Papworth Hospital NHS foundation Trust
Papworth Everard, Cambridge, United Kingdom, CV23 3RE
Blackpool Victoria Hospital
Blackpool, Lancashire, United Kingdom, FY8 8NR
Sponsors and Collaborators
Edwards Lifesciences
Study Director: Jan Champion Edwards Lifesciences
  More Information

Responsible Party: Edwards Lifesciences Identifier: NCT01171625     History of Changes
Other Study ID Numbers: 2007-08
Study First Received: July 26, 2010
Last Updated: September 20, 2016

Keywords provided by Edwards Lifesciences:
PERIMOUNT, Aortic valve replacement/regurgitation

Additional relevant MeSH terms:
Heart Failure
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Aortic Valve Stenosis
Aortic Valve Insufficiency
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Heart Valve Diseases
Ventricular Outflow Obstruction processed this record on July 25, 2017